Oxygenta Pharmaceutical Limited (BOM:524636)
India · Delayed Price · Currency is INR 52.11
+1.20 (2.36%)
At close: Jul 27, 2026
Oxygenta Pharmaceutical Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | -175.72 | -96.83 | -34.79 | -115.71 | -6.1 |
Depreciation & Amortization | 23.23 | 8.16 | 26.61 | 20.52 | 15.91 |
Provision & Write-off of Bad Debts | - | 7.72 | - | - | - |
Other Operating Activities | 12.56 | -11.31 | -87.45 | 16.81 | 9.2 |
Change in Accounts Receivable | -56.15 | 11.8 | 31.96 | -85.84 | 0.34 |
Change in Inventory | -89.08 | -67.97 | -20.11 | -44.22 | 48.31 |
Change in Accounts Payable | 189.75 | 69.07 | -39.57 | 212.07 | -90.94 |
Change in Other Net Operating Assets | -182.12 | 105.39 | -7.13 | -19.96 | 6.48 |
Operating Cash Flow | -277.53 | 26.03 | -130.5 | -16.34 | -16.8 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -128.57 | -113.92 | -41.06 | -96.45 | -49.46 |
Sale of Property, Plant & Equipment | - | 1.2 | - | - | - |
Investment in Securities | -16.1 | - | - | - | - |
Other Investing Activities | 0.8 | 0.22 | 0.18 | 0.05 | 0.04 |
Investing Cash Flow | -143.87 | -112.49 | -40.88 | -96.4 | -49.41 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | - | 324.78 | - | - | - |
Long-Term Debt Issued | 537.64 | - | - | 127.12 | 32.57 |
Total Debt Issued | 537.64 | 324.78 | - | 127.12 | 32.57 |
Short-Term Debt Repaid | -64.29 | - | - | - | - |
Long-Term Debt Repaid | - | -274.79 | -107.6 | - | - |
Total Debt Repaid | -64.29 | -274.79 | -107.6 | - | - |
Net Debt Issued (Repaid) | 473.34 | 49.99 | -107.6 | 127.12 | 32.57 |
Issuance of Common Stock | - | 54.5 | 289.23 | - | 40 |
Other Financing Activities | -47.77 | -17.82 | -10.32 | -14.88 | -9.25 |
Financing Cash Flow | 425.57 | 86.67 | 171.32 | 112.24 | 63.32 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | - | 0 | - | - | 0 |
Net Cash Flow | 4.17 | 0.21 | -0.05 | -0.5 | -2.89 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -406.1 | -87.89 | -171.55 | -112.79 | -66.26 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -35.94% | -8.04% | -43.28% | -36.40% | -10.95% |
Free Cash Flow Per Share | -10.98 | -2.44 | -5.35 | -7.94 | -5.20 |
Levered Free Cash Flow | -362.36 | -54.68 | -110.47 | -95.62 | -55.73 |
Unlevered Free Cash Flow | -332.51 | -42.07 | -100.59 | -86.4 | -50.01 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 47.77 | 17.82 | 15.94 | 14.88 | 9.25 |
Cash Income Tax Paid | -1.59 | 1.6 | - | - | - |
Change in Working Capital | -137.6 | 118.29 | -34.86 | 62.05 | -35.81 |